Dermatofibroma differential diagnosis

	Dermatofibroma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dermatofibroma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dermatofibroma differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dermatofibroma differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dermatofibroma differential diagnosis
CDC on Dermatofibroma differential diagnosis
Dermatofibroma differential diagnosis in the news
Blogs on Dermatofibroma differential diagnosis
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Dermatofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Differential Diagnosis

Deep penetrating dermatofibroma may be difficult to distinguish, even histologically, from rare malignant fibrohistocytic tumors e.g dermatofibrosarcoma protuberans^[1]

Neoplasm	CD34	Stromelysin-3^[2]	Factor XIIIa
Dermatofibroma	+	+	+
Dermatofibrosarcoma protuberans	+	-	-

↑ Hanly AJ, Jordà M, Elgart GW, Badiavas E, Nassiri M, Nadji M (2006). "High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors". Arch. Pathol. Lab. Med. 130 (6): 831–4. doi:10.1043/1543-2165(2006)130[831:HPAEDR]2.0.CO;2. PMID 16740036. Unknown parameter |month= ignored (help)
↑ Kim HJ, Lee JY, Kim SH; et al. (2007). "Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34". Br. J. Dermatol. 157 (2): 319–24. doi:10.1111/j.1365-2133.2007.08033.x. PMID 17596171. Unknown parameter |month= ignored (help)